These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 34395293)

  • 1. Incorporating PSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment: a Multidisciplinary Perspective.
    Ng TSC; Gao X; Salari K; Zlatev DV; Heidari P; Kamran SC
    Front Oncol; 2021; 11():722277. PubMed ID: 34395293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PSMA Theranostics: Current Landscape and Future Outlook.
    Zhang H; Koumna S; Pouliot F; Beauregard JM; Kolinsky M
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of PSMA-targeted imaging and therapy.
    Wang H; Li G; Zhao J; Eiber M; Tian R
    Front Oncol; 2023; 13():1230251. PubMed ID: 38264741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting.
    Miyahira AK; Pienta KJ; Babich JW; Bander NH; Calais J; Choyke P; Hofman MS; Larson SM; Lin FI; Morris MJ; Pomper MG; Sandhu S; Scher HI; Tagawa ST; Williams S; Soule HR
    Prostate; 2020 Nov; 80(15):1273-1296. PubMed ID: 32865839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
    Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
    Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing the Goal Posts: Prostate-specific Membrane Antigen Targeted Theranostics in Prostate Cancer.
    Emmett L
    Semin Oncol Nurs; 2020 Aug; 36(4):151052. PubMed ID: 32674976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer.
    Luining WI; Cysouw MCF; Meijer D; Hendrikse NH; Boellaard R; Vis AN; Oprea-Lager DE
    Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.
    Rowe SP; Gorin MA; Allaf ME; Pienta KJ; Tran PT; Pomper MG; Ross AE; Cho SY
    Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):223-30. PubMed ID: 27136743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate Cancer Theranostics: PSMA Targeted Therapy.
    Seifert R; Alberts IL; Afshar-Oromieh A; Rahbar K
    PET Clin; 2021 Jul; 16(3):391-396. PubMed ID: 34053583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in PSMA theranostics.
    Jeitner TM; Babich JW; Kelly JM
    Transl Oncol; 2022 Aug; 22():101450. PubMed ID: 35597190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond.
    Hyväkkä A; Virtanen V; Kemppainen J; Grönroos TJ; Minn H; Sundvall M
    Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34067046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy.
    Jones W; Griffiths K; Barata PC; Paller CJ
    Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32466595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PSMA-Targeted Nanotheranostics for Imaging and Radiotherapy of Prostate Cancer.
    Meher N; VanBrocklin HF; Wilson DM; Flavell RR
    Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37259457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives.
    El Fakiri M; Geis NM; Ayada N; Eder M; Eder AC
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific membrane antigen theranostics in advanced prostate cancer: an evolving option.
    Mayor N; Sathianathen NJ; Buteau J; Koschel S; Antón Juanilla M; Kapoor J; Azad A; Hofman MS; Murphy DG
    BJU Int; 2020 Nov; 126(5):525-535. PubMed ID: 32559353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dawn of Theranostics in Myanmar (Dream, Reality, and Constraint).
    Myint K; Thein TM; Phyu TK; Maung W
    Nucl Med Mol Imaging; 2019 Feb; 53(1):42-46. PubMed ID: 30828400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer.
    Plichta KA; Graves SA; Buatti JM
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34829977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PSMA Theranostics: Current Status and Future Directions.
    Rahbar K; Afshar-Oromieh A; Jadvar H; Ahmadzadehfar H
    Mol Imaging; 2018; 17():1536012118776068. PubMed ID: 29873291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSMA Theranostics: A "Must Have" in Every Prostate Cancer Center. Illustration of Two Clinical Cases and Review of the Literature.
    Cytawa W; Hartrampf P; Lass P; Kircher M; Polat B; Buck AK; Lapa C
    Clin Genitourin Cancer; 2021 Aug; 19(4):e235-e247. PubMed ID: 33906800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.